Metabolon and Mayo Clinic will jointly research disease biomarkers and develop novel diagnostic tests for use in Mayo Clinic’s nationwide...

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards. MORRISVILLE, N.C. –...

An accomplished leader in laboratory innovations and diagnostics, Houseman will enable process efficiency and capability across Metabolon testing and operations....

Metabolon Partnership with University of Maryland School of Medicine Amish Research Program Leverages Metabolomics to Identify Novel Biomarkers MORRISVILLE, N.C....

New collaboration between Metabolon and King’s College London to analyze TwinsUK clinical data, gain insights into the interplay between the...

Sean Iverson will drive marketing strategy and execution for the company's expanding product portfolio.

“We are thrilled to welcome Gerry to Metabolon during this strategic growth phase as we expand the use of metabolomics across the life sciences, including drug discovery and development. Gerry has a strong track record of success as a multi-faceted CFO, leading companies spanning the high-tech, biotech, medtech, and manufacturing sectors,” said Rohan Hastie, Ph.D., President and CEO of Metabolon.

As a leading biobank research project based in Finland, FinnGen will incorporate deep metabolomic datasets to better understand how genetic drivers of disease may impact biological function and influence disease progression.

Metabolon will collaborate with Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center (BIDMC) in a first-of-its-kind Lactation Lab, providing comprehensive metabolomic profiles to enhance understanding of the biology underlying lactation to identify solutions to improve maternal and infant health.

In just 16 months, physicians went from identifying a novel rare disease in three-year-old Marley to successfully treating her with a drug previously used to treat African sleeping sickness and pediatric cancer.

Metabolon’s Microbiome SmartPanel demystifies the gut microbiome by zeroing in on biologically relevant microbial and host-derived metabolites, along with xenobiotic molecules, to reveal deep insight into microbiome function and its impact on host health. The proprietary Heliogram™ visualization tool allows users to explore 13 microbiome pathways for rapid connectivity to the impact of therapeutic interventions on the host microbiome.

Dr. Sarangarajan supports Metabolon’s mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research in all its applications by leading the team to identify R&D applications across biopharma and diagnostics.